{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.6","upperLimit":"28.9","value":"24.7"},{"groupId":"OG001","lowerLimit":"16.4","upperLimit":"21.4","value":"19.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Defined as time from randomization to death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"Up to 60.1 months","title":"Overall Survival (OS) at Time of Final Analysis","type":"SECONDARY","unitOfMeasure":"months"}